Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma

Hiroki Sato, Masakiyo Sakaguchi, Hiromasa Yamamoto, Shuta Tomida, Keisuke Aoe, Kazuhiko Shien, Takahiro Yoshioka, Kei Namba, Hidejiro Torigoe, Junichi Sou, Kazunori Tsukuda, Hiroyuki Tao, Kazunori Okabe, Shinichiro Miyoshi, Harvey I. Pass, Shinichi Toyooka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumor with an unfavorable prognosis. The standard therapeutic approaches are limited to surgery, chemotherapy, and radiotherapy. Because the consequent clinical outcome is often unsatisfactory, a different approach in MPM treatment is required. S100A11, a Ca2+-binding small protein with two EF-hands, is frequently upregulated in various human cancers. Interestingly, it has been found that intracellular and extracellular S100A11 have different functions in cell viability. In this study, we focused on the impact of extracellular S100A11 in MPM and explored the therapeutic potential of an S100A11-targeting strategy. We examined the secretion level of S100A11 in various kinds of cell lines by enzyme-linked immunosorbent assay. Among them, six out of seven MPM cell lines actively secreted S100A11, whereas normal mesothelial cell lines did not secrete it. To investigate the role of secreted S100A11 in MPM, we inhibited its function by neutralizing S100A11 with an anti-S100A11 antibody. Interestingly, the antibody significantly inhibited the proliferation of S100A11-secreting MPM cells in vitro and in vivo. Microarray analysis revealed that several pathways including genes involved in cell proliferation were negatively enriched in the antibody-treated cell lines. In addition, we examined the secretion level of S100A11 in various types of pleural effusions. We found that the secretion of S100A11 was significantly higher in MPM pleural effusions, compared to others, suggesting the possibility for the use of S100A11 as a biomarker. In conclusion, our results indicate that extracellular S100A11 plays important roles in MPM and may be a therapeutic target in S100A11-secreting MPM.

Original languageEnglish
Article number0017
JournalOncogenesis
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Cell Line
Therapeutics
Pleural Effusion
EF Hand Motifs
Malignant Mesothelioma
Antibodies
Microarray Analysis
Anti-Idiotypic Antibodies
Neoplasms
Cell Survival
Carrier Proteins
Radiotherapy
Biomarkers
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Drug Therapy
Genes
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. / Sato, Hiroki; Sakaguchi, Masakiyo; Yamamoto, Hiromasa; Tomida, Shuta; Aoe, Keisuke; Shien, Kazuhiko; Yoshioka, Takahiro; Namba, Kei; Torigoe, Hidejiro; Sou, Junichi; Tsukuda, Kazunori; Tao, Hiroyuki; Okabe, Kazunori; Miyoshi, Shinichiro; Pass, Harvey I.; Toyooka, Shinichi.

In: Oncogenesis, Vol. 7, No. 1, 0017, 01.01.2018.

Research output: Contribution to journalArticle

Sato, H, Sakaguchi, M, Yamamoto, H, Tomida, S, Aoe, K, Shien, K, Yoshioka, T, Namba, K, Torigoe, H, Sou, J, Tsukuda, K, Tao, H, Okabe, K, Miyoshi, S, Pass, HI & Toyooka, S 2018, 'Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma', Oncogenesis, vol. 7, no. 1, 0017. https://doi.org/10.1038/s41389-017-0017-3
Sato, Hiroki ; Sakaguchi, Masakiyo ; Yamamoto, Hiromasa ; Tomida, Shuta ; Aoe, Keisuke ; Shien, Kazuhiko ; Yoshioka, Takahiro ; Namba, Kei ; Torigoe, Hidejiro ; Sou, Junichi ; Tsukuda, Kazunori ; Tao, Hiroyuki ; Okabe, Kazunori ; Miyoshi, Shinichiro ; Pass, Harvey I. ; Toyooka, Shinichi. / Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. In: Oncogenesis. 2018 ; Vol. 7, No. 1.
@article{d56b96337a2f41e3ad6a085fbc603030,
title = "Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma",
abstract = "Malignant pleural mesothelioma (MPM) is an aggressive tumor with an unfavorable prognosis. The standard therapeutic approaches are limited to surgery, chemotherapy, and radiotherapy. Because the consequent clinical outcome is often unsatisfactory, a different approach in MPM treatment is required. S100A11, a Ca2+-binding small protein with two EF-hands, is frequently upregulated in various human cancers. Interestingly, it has been found that intracellular and extracellular S100A11 have different functions in cell viability. In this study, we focused on the impact of extracellular S100A11 in MPM and explored the therapeutic potential of an S100A11-targeting strategy. We examined the secretion level of S100A11 in various kinds of cell lines by enzyme-linked immunosorbent assay. Among them, six out of seven MPM cell lines actively secreted S100A11, whereas normal mesothelial cell lines did not secrete it. To investigate the role of secreted S100A11 in MPM, we inhibited its function by neutralizing S100A11 with an anti-S100A11 antibody. Interestingly, the antibody significantly inhibited the proliferation of S100A11-secreting MPM cells in vitro and in vivo. Microarray analysis revealed that several pathways including genes involved in cell proliferation were negatively enriched in the antibody-treated cell lines. In addition, we examined the secretion level of S100A11 in various types of pleural effusions. We found that the secretion of S100A11 was significantly higher in MPM pleural effusions, compared to others, suggesting the possibility for the use of S100A11 as a biomarker. In conclusion, our results indicate that extracellular S100A11 plays important roles in MPM and may be a therapeutic target in S100A11-secreting MPM.",
author = "Hiroki Sato and Masakiyo Sakaguchi and Hiromasa Yamamoto and Shuta Tomida and Keisuke Aoe and Kazuhiko Shien and Takahiro Yoshioka and Kei Namba and Hidejiro Torigoe and Junichi Sou and Kazunori Tsukuda and Hiroyuki Tao and Kazunori Okabe and Shinichiro Miyoshi and Pass, {Harvey I.} and Shinichi Toyooka",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41389-017-0017-3",
language = "English",
volume = "7",
journal = "Oncogenesis",
issn = "2157-9024",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma

AU - Sato, Hiroki

AU - Sakaguchi, Masakiyo

AU - Yamamoto, Hiromasa

AU - Tomida, Shuta

AU - Aoe, Keisuke

AU - Shien, Kazuhiko

AU - Yoshioka, Takahiro

AU - Namba, Kei

AU - Torigoe, Hidejiro

AU - Sou, Junichi

AU - Tsukuda, Kazunori

AU - Tao, Hiroyuki

AU - Okabe, Kazunori

AU - Miyoshi, Shinichiro

AU - Pass, Harvey I.

AU - Toyooka, Shinichi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Malignant pleural mesothelioma (MPM) is an aggressive tumor with an unfavorable prognosis. The standard therapeutic approaches are limited to surgery, chemotherapy, and radiotherapy. Because the consequent clinical outcome is often unsatisfactory, a different approach in MPM treatment is required. S100A11, a Ca2+-binding small protein with two EF-hands, is frequently upregulated in various human cancers. Interestingly, it has been found that intracellular and extracellular S100A11 have different functions in cell viability. In this study, we focused on the impact of extracellular S100A11 in MPM and explored the therapeutic potential of an S100A11-targeting strategy. We examined the secretion level of S100A11 in various kinds of cell lines by enzyme-linked immunosorbent assay. Among them, six out of seven MPM cell lines actively secreted S100A11, whereas normal mesothelial cell lines did not secrete it. To investigate the role of secreted S100A11 in MPM, we inhibited its function by neutralizing S100A11 with an anti-S100A11 antibody. Interestingly, the antibody significantly inhibited the proliferation of S100A11-secreting MPM cells in vitro and in vivo. Microarray analysis revealed that several pathways including genes involved in cell proliferation were negatively enriched in the antibody-treated cell lines. In addition, we examined the secretion level of S100A11 in various types of pleural effusions. We found that the secretion of S100A11 was significantly higher in MPM pleural effusions, compared to others, suggesting the possibility for the use of S100A11 as a biomarker. In conclusion, our results indicate that extracellular S100A11 plays important roles in MPM and may be a therapeutic target in S100A11-secreting MPM.

AB - Malignant pleural mesothelioma (MPM) is an aggressive tumor with an unfavorable prognosis. The standard therapeutic approaches are limited to surgery, chemotherapy, and radiotherapy. Because the consequent clinical outcome is often unsatisfactory, a different approach in MPM treatment is required. S100A11, a Ca2+-binding small protein with two EF-hands, is frequently upregulated in various human cancers. Interestingly, it has been found that intracellular and extracellular S100A11 have different functions in cell viability. In this study, we focused on the impact of extracellular S100A11 in MPM and explored the therapeutic potential of an S100A11-targeting strategy. We examined the secretion level of S100A11 in various kinds of cell lines by enzyme-linked immunosorbent assay. Among them, six out of seven MPM cell lines actively secreted S100A11, whereas normal mesothelial cell lines did not secrete it. To investigate the role of secreted S100A11 in MPM, we inhibited its function by neutralizing S100A11 with an anti-S100A11 antibody. Interestingly, the antibody significantly inhibited the proliferation of S100A11-secreting MPM cells in vitro and in vivo. Microarray analysis revealed that several pathways including genes involved in cell proliferation were negatively enriched in the antibody-treated cell lines. In addition, we examined the secretion level of S100A11 in various types of pleural effusions. We found that the secretion of S100A11 was significantly higher in MPM pleural effusions, compared to others, suggesting the possibility for the use of S100A11 as a biomarker. In conclusion, our results indicate that extracellular S100A11 plays important roles in MPM and may be a therapeutic target in S100A11-secreting MPM.

UR - http://www.scopus.com/inward/record.url?scp=85041007020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041007020&partnerID=8YFLogxK

U2 - 10.1038/s41389-017-0017-3

DO - 10.1038/s41389-017-0017-3

M3 - Article

AN - SCOPUS:85041007020

VL - 7

JO - Oncogenesis

JF - Oncogenesis

SN - 2157-9024

IS - 1

M1 - 0017

ER -